Discontinuation of Therapy With Bupropion SR
نویسندگان
چکیده
منابع مشابه
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
This 56-week, randomized, placebo-controlled trial examined the efficacy and safety of naltrexone plus bupropion as an adjunct to intensive behavior modification (BMOD). A total of 793 participants (BMI = 36.5 ± 4.2 kg/m²) was randomly assigned in a 1:3 ratio to: (i) placebo + BMOD (N = 202); or (ii) naltrexone sustained-release (SR, 32 mg/day), combined with bupropion SR (360 mg/day) plus BMOD...
متن کاملBupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness.
professionals, Health Canada and GlaxoSmithKline stated that 1127 reports of suspected adverse drug reactions for bupropion were received between May 1998 and May 28, 2001. Included were reports of 19 deaths (including 1 case of liver failure, 1 case of myocarditis, 3 cases of suicide), 172 reports of seizures or convulsions and 37 reports of serum-sickness-like reactions. Although cause-and-ef...
متن کاملThe use of bupropion SR in cigarette smoking cessation
Cigarette smoking remains the largest preventable cause of premature death in developed countries. Until recently nicotine replacement therapy (NRT) has been the only recognised form of treatment for smoking cessation. Bupropion, the first non-nicotine based drug for smoking cessation was licensed in the United States of America (US) in 1997 and in the United Kingdom (UK) in 2000 for smoking ce...
متن کاملMethod‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
OBJECTIVE This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks. METHODS In this phase 3b, randomized, open-label, controlled study, subjects received NB + CLI or usual care (standard diet/exercise advice) for 26 weeks. NB subjects not achieving 5%...
متن کاملBupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.
AIMS To investigate the safety and efficacy of bupropion sustained release (bupropion SR) in promoting abstinence from smoking in subjects with cardiovascular disease (CVD). METHODS Six hundred twenty-nine subjects with CVD who smoked >/=10 cigarettes/day were randomised in a double-blind, multicentre study to receive bupropion SR (150 mg twice daily) or placebo for 7 weeks, with a follow-up ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Primary Care Companion to The Journal of Clinical Psychiatry
سال: 1999
ISSN: 1523-5998
DOI: 10.4088/pcc.v01n0507a